Dear Mr. President | Association for Accessible Medicines
AAM Statement - President Trump’s Blueprint to Lower Drug Prices

Dear Mr. President

“To speed access to breakthrough cures and affordable generic drugs, last year the FDA approved more new and generic drugs and medical devices than ever before in our history.”

-Donald Trump, State of the Union, January 30, 2018

In his first State of the Union, President Donald Trump stressed the importance of approving safe and affordable generic drugs.

FDA approving generics and biosimilar medicines is an important first step in bringing down drug prices, one of the President’s most important commitments to the American people. To fully realize that promise, we must have policies that ensure access to markets and sustainable competition for these drugs.

Unfortunately, some brand drug makers now wrongly withhold from generic manufacturers the samples required by our companies to even start developing and getting approval for an affordable competitor medicine. That’s why AAM has written to the president asking for his support in passing the CREATES Act, which will curb this anticompetitive practice. Until these shenanigans are stopped, American patients and their families will continue to pay higher prices than they would if generic and biosimilar treatment options were available.

Since the aim of CREATES is in sync with the administration’s priority to reduce the price of prescription drugs, we respectfully urge the President to publicly support its passage.

View Letter

 

Erica Klinger


By Erica Klinger, AAM Marketing Director

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.